In another study, AI achieved positive predictive values between 75.40% and 80.40% for additional EGFR-TKI survival benefit prediction, when using the probability score of 0.2 as threshold, with higher scores (>0.2) indicating a better prognosis; this study depicts the potential of AI to identify sub-groups of benefiting patients through decoding the commonalities in pre-therapy CT images from stage IV EGFR-mutant NSCLC patients receiving additional survival benefit from EGFR-TKIs [216]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.